# Italian pharma push, biosimilars & insurance growth

> Live situation record from CLSTR: https://clstr.news/situations/italian-pharmaceutical-sector-expansion
> Updated: 2026-08-06T13:27:50.000Z. Sources: 121. Developments: 25.

The Italian government continues to treat pharmaceuticals as a strategic growth engine and a pillar of health security. Recent Senate conferences highlighted the need for patient‑centred innovation and noted record export growth – 7.2 % to the United States and 3.3 % globally in 2025 – while stressing regulatory bottlenecks and the lack of an early‑access pathway for advanced therapies. Industry leaders are pushing a digital transformation agenda. A June Adnkronos talk and the 65th AFI symposium underscored the urgency of specialised AI and data‑analytics skills, while the Italian Forum of Scientific Societies reported that AI could cut drug‑development costs by 25 % and timelines by 40 %. Bayer Italy and other firms are leveraging AI to accelerate molecule discovery, aiming for a 40 % reduction in time‑to‑market by 2030. AIFA and the pharmacists’ federation (FOFI) have signed a three‑year pact to deliver AI‑driven regulatory and shortage information to community pharmacists. Regional biotech activity, especially in Lazio, is being promoted as a driver of export growth and competitiveness. At the same time, the Gimbe Foundation warned that Italy lags on EU‑required digital traceability of medicines, a gap that could affect safety. Biosimilars now cover about 55 % of the market, with consumption projected to rise 7 % in 2025, but concerns persist over single‑award procurement and supply resilience. AIFA’s draft reform to price drugs at the cheapest active‑ingredient level sparked strong opposition from Farmindustria, Egualia and the Senate Finance Committee, which warned of margin erosion and patient cost shifts of up to €1 billion. Private health‑insurance coverage reached €4.9 bn in 2025, covering roughly 40 % of Italians, while supplemental pharmacy insurance schemes (Fasifar, Emapi) are being reviewed. The sector also saw a 35 % jump in antidiabetic drug spending, driven by obesity‑related use of semaglutide and tirzepatide.

## Timeline

### 2026-08-06: Italy drug spending reaches €39.3 bn in 2025, antidiabetic use soars

Italy’s 2025 pharmaceutical spend rose 6% to €39.3 bn, with public funds at €28.4 bn and out‑of‑pocket at €10.7 bn; antidiabetic drug spending jumped 35% to €1.59 bn, driven by semaglutide and tirzepatide.

8 sources. https://clstr.news/cluster/italy-sees-35-jump-in-antidiabetic-drug-spending-driven-by-obesity-use

### 2026-07-20: AIFA's drug pricing overhaul faces industry and political criticism in Italy

AIFA plans to revamp Italy's drug reimbursement list, limiting payments to the cheapest active ingredient within broader therapeutic groups. Politicians and pharma groups warn the move could shift costs to the

45 sources. https://clstr.news/cluster/italian-health-ministry-suspends-tariff-reform-after-court-blocks-plan

### 2026-07-17: Italian generic drug association cites €7.4 bn state savings and calls for payback reform

Egualia reports €7.4 bn saved by generics and biosimilars, 11 k jobs, and calls for pay‑back reform to protect margins and boost domestic drug production in Italy.

6 sources. https://clstr.news/cluster/italian-generic-drug-association-cites-74-bn-state-savings-and-calls-for-payback-reform

### 2026-07-14: Italian drug regulator AIFA adds detailed market status to 'Cerca un Farmaco' service

AIFA’s ‘Cerca un farmaco’ portal now shows per‑pack commercialisation status—available, unavailable, scarce or never marketed—and adds shortage reasons, timelines and guidance for pharmacists.

5 sources. https://clstr.news/cluster/italian-drug-regulator-aifa-adds-detailed-market-status-to-cerca-un-farmaco-service

### 2026-07-14: Italian officials seek to curb Teva drug use in public pharmacies

Italian officials in Fano and the national parliament are urging limits on Teva drugs in public pharmacies and calling for a balanced drug formulary that protects innovative treatments while controlling costs.

5 sources. https://clstr.news/cluster/italian-officials-seek-to-curb-teva-drug-use-in-public-pharmacies

### 2026-07-11: Italian insurance market grows while trust between firms erodes

Italy’s insurance credit and surety market is expanding—global forecast $31.85 bn by 2031 and domestic premiums up 9.2%—but a trust crisis is straining SME access to guarantees, prompting calls for cultural re‑

2 sources. https://clstr.news/cluster/italian-insurance-market-grows-while-trust-between-firms-erodes

### 2026-07-08: Italy hosts forum on life‑science competitiveness and drug access

A Rome forum gathered government, academia and pharma to discuss Italy’s life‑science competitiveness, MFN drug pricing and ways to speed patient access, citing a widening EU‑US research gap.

7 sources. https://clstr.news/cluster/rome-conference-examines-lifescience-competitiveness-and-mfn-policy

### 2026-07-07: Italian pharmaceutical sector sees modest retail growth but strong export surge

Italy’s pharma market grew modestly in retail while exports surged 28.5% in 2025, highlighting strong OTC sales, dominant brick‑and‑mortar pharmacies and a rising need for specialised workforce skills.

2 sources. https://clstr.news/cluster/italian-pharmaceutical-sector-sees-modest-retail-growth-but-strong-export-surge

### 2026-07-06: Italy's private health insurance market expands as citizens turn to self‑care

Italy's health insurance market surged to €4.9 bn in 2025, with 40% of Italians now covered, as long public wait times drive self‑medication and demand for hybrid pharmacy services across Europe.

4 sources. https://clstr.news/cluster/italys-private-health-insurance-market-expands-as-citizens-turn-to-selfcare

### 2026-07-01: Italy's pharmacy sector examines supplemental health insurance differences

Italy's pharmacy sector compares two supplemental health insurance schemes, Fasifar and Emapi, while broader industry discussions cover legislation, biosimilars, AI in drug development, and medical device采购.

2 sources. https://clstr.news/cluster/italys-pharmacy-sector-examines-supplemental-health-insurance-differences

### 2026-06-29: Simona Autunnali says Italy's drug formulary update must not mask cost‑saving motives

Snami chief Simona Autunnali urges Italy's drug formulary revision to prioritize clinical appropriateness over cost cuts, while a new pharmacist guide promotes evidence‑based care for minor ailments.

3 sources. https://clstr.news/cluster/simona-autunnali-says-italys-drug-formulary-update-must-not-mask-costsaving-motives

### 2026-06-26: Italian authorities reject reimbursement for new Alzheimer drugs while emphasizing biosimilar cost savings

Italy’s drug agency rejects reimbursement for new Alzheimer antibodies over modest benefit, while Sandoz stresses biosimilars’ €56 bn EU savings and calls for strong governance.

11 sources. https://clstr.news/cluster/sandoz-italy-ceo-says-biosimilars-key-to-drug-spending-governance

### 2026-06-23: Italy's drug policy wrestles with rising costs and biosimilar sustainability

Italy's biosimilar success faces procurement concentration, while lawmakers decry rising drug costs and plans to shift reimbursements onto citizens.

4 sources. https://clstr.news/cluster/italys-drug-policy-wrestles-with-rising-costs-and-biosimilar-sustainability

### 2026-06-22: Farmindustria emphasises pharma as a strategic asset for Italy and Europe

Farmindustria re‑elected Marcello Cattani, warns pharma spending is an investment; round‑table in Rome flags drug supply chains as strategic for Italy’s security and European autonomy, urging regulatory support

18 sources. https://clstr.news/cluster/italys-pharma-and-retail-sectors-drive-economic-growth

### 2026-06-19: Italy's pharmaceutical spending reforms risk up to €1 billion extra cost

Italy aims to curb soaring drug costs by expanding generic equivalents and a new reference‑price system, but a €4.7 bn budget overshoot and a potential €1 bn patient burden raise concerns.

2 sources. https://clstr.news/cluster/italys-pharmaceutical-spending-reforms-risk-up-to-1-billion-extra-cost

### 2026-06-17: AIFA and FOFI sign pact to boost AI‑driven digital tools for Italian pharmacists

AIFA and FOFI have signed a three‑year pact to share drug data via Italy’s Pdnd platform and launch an AI service for pharmacists, aiming to improve chronic‑care monitoring and tackle medication shortages.

3 sources. https://clstr.news/cluster/aifa-and-fofi-sign-pact-to-boost-aidriven-digital-tools-for-italian-pharmacists

### 2026-06-17: Italy's Health Ministry flags forensic medicine roadmap and pharma traceability lag

Italy’s Health Ministry launches a forensic‑medicine strategic plan while a Gimbe report warns the country lags in EU‑required digital drug traceability, risking public‑health safety.

3 sources. https://clstr.news/cluster/italys-health-ministry-flags-forensic-medicine-roadmap-and-pharma-traceability-lag

### 2026-06-15: Italy accelerates drug discovery with AI and funds rare‑disease research

AI is speeding Italian drug development while AIFA awards €17.5 million to 19 rare‑disease research projects, aiming to cut costs and expand treatment options.

2 sources. https://clstr.news/cluster/italy-accelerates-drug-discovery-with-ai-and-funds-raredisease-research

### 2026-06-12: Bayer Italy CEO Arianna Gregis details AI‑driven innovation and export push

Bayer Italy CEO Arianna Gregis says the firm’s strategy hinges on innovation, AI‑driven drug development and strategic alliances, with its Garbagnate Milanese plant producing 8 bn tablets a year for export and,

2 sources. https://clstr.news/cluster/bayer-italy-ceo-arianna-gregis-details-aidriven-innovation-and-export-push

### 2026-06-11: Italian health sector boosts innovation with clinical engineering focus and upgraded pharmacy labs

Italy advances health innovation: clinical engineers link new tech to care, and Reggio Emilia’s pharmacy labs are upgraded for advanced, safe therapies.

2 sources. https://clstr.news/cluster/italian-health-sector-boosts-innovation-with-clinical-engineering-focus-and-upgraded-pharmacy-labs

### 2026-06-09: Italy's pharma sector calls for digital, AI and skill reforms to boost competitiveness

Italy’s pharma industry urges digital, AI and regulatory reforms, plus focused skill training, to maintain EU leadership and attract global R&D investment.

4 sources. https://clstr.news/cluster/italys-pharma-sector-calls-for-digital-ai-and-skill-reforms-to-boost-competitiveness

### 2026-06-08: Lazio biotech sector fuels regional economic growth and competitiveness

Lazio’s biotech and pharma cluster, backed by universities and firms like Bayer Italia, is driving regional growth, high‑skill jobs and export strength while seeking faster regulation and more R&D investment.

2 sources. https://clstr.news/cluster/lazio-biotech-sector-fuels-regional-economic-growth-and-competitiveness

### 2026-06-04: Italian scientists say AI can cut drug‑development costs by 25% and timelines by 40%

Italian experts say AI can cut drug‑development costs by 25% and reduce timelines by 40%, urging faster tech transfer and a public‑private hub to boost Italy’s pharma competitiveness.

4 sources. https://clstr.news/cluster/italian-scientists-say-ai-can-cut-drugdevelopment-costs-by-25-and-timelines-by-40

### 2026-06-04: Italian Pharma Leaders Discuss Skills and AI at June 9 Adnkronos Talk

Italian pharma leaders will discuss AI, big data, talent and training at a live Adnkronos talk on 9 June, seeking a skills roadmap for the sector.

3 sources. https://clstr.news/cluster/italian-pharma-leaders-discuss-skills-and-ai-at-june-9-adnkronos-talk

### 2026-05-21: Italy positions pharmaceutical industry as growth engine while stressing patient‑centred innovation

Italy’s pharma sector is hailed as an economic driver, with record export growth and €4.5 bn R&D spending, while experts stress patient‑centred access and faster EU regulations.

23 sources. https://clstr.news/cluster/eu-advances-new-drug-regulations-to-keep-pace-with-innovation-says-aifa

---
Cite as: Italian pharma push, biosimilars & insurance growth. CLSTR, https://clstr.news/situations/italian-pharmaceutical-sector-expansion